The worldwide insulin market is currently monopolized by three major companies, and high costs pose a treatment barrier for many people with diabetes. In fact, of the 100 million people living with diabetes, it is estimated that half find … Read More
The FDA has given its approval to LUSDUNA Nexvue, an injectable basal insulin manufactured by Merck. This insulin is a biologic insulin glargine. The FDA’s approval is only tentative, however, because Merck is currently in the middle of… Read More
The elderly often have some difficultly in successfully injecting insulin themselves. However, a cognitive test that asks patients to recall animal names has proven to be a strong indicator in showing which patients can successfully perform… Read More
Lyon and Indianapolis, May 31, 2016 – Adocia (Euronext Paris: ADOC) and Eli Lilly and Company (NYSE: LLY) announced today positive topline results from a Phase 1 clinical trial evaluating BioChaperone Lispro, an ultra-rapid formulation
A recent study has found that insulin treatment is not responsible for the poorer health outcomes after stenting in patients with type 2 diabetes. However, it was suggested that everolimus-eluting stents might be a better choice for patients… Read More
Listen to today’s podcast here!
New research shows that women who are taking insulin for diabetes treatment are at a higher risk of dense breasts. Researchers from the University of Southern Denmark in Esbjerg are responsible for the… Read More
Researchers recently completed a study to find out how the risk of fracture differed with the type of insulin therapy used by people with type 2 diabetes. While it is known that there is an increased risk of fracture associated with type 2 diabetes,… Read More